News Website

Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive

Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive

Published: April 12, 2026, 9:28 p.m.

Read Full Article

Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma - OncLive

Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma OncLive

Published: April 12, 2026, 9:10 p.m.

Read Full Article

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.

Read Full Article

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive

Published: April 12, 2026, 12:58 a.m.

Read Full Article

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.

Read Full Article

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.

Read Full Article

In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Published: April 11, 2026, 11 a.m.

Read Full Article

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.

Read Full Article

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.

Read Full Article

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.

Read Full Article

Latest Articles

Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive

Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Subscribe to Our Newsletter